Requirements for primary T cell activation.
Melton
L B
LB
Charles A. Dana Research Institute, Department of Medicine, Beth Israel Hospital, Boston, MA 02215.
Lakkis
F G
FG
Deloria
D
D
Williams
J W
JW
Strom
T B
TB
D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D017252:CD3 Complex; D002478:Cells, Cultured; D004261:DNA Replication / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007700:Kinetics; D008213:Lymphocyte Activation; D010835:Phytohemagglutinins / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007375:Interleukin-1; D010835:Phytohemagglutinins; D011948:Receptors, Antigen, T-Cell; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate